Life Sciences BPO Market Is Expected To Reach US$286.3 bn By The End Of 2023

The presence of a large number of contract research organizations (CROs) and contract manufacturing organizations (CMOs) that offer end-to-end business solutions to life science companies has rendered a highly competitive landscape to the global life science BPO market. In order to sustain their competitiveness, the most prominent companies in the market such as Accenture plc, Cognizant Technology Solutions, and Infosys Limited are offering bundled services to their clients. Moreover, adopting innovative technologies is a popular trend among the leading market players. According to a new study by Transparency Market Research (TMR), these factors have kept the level of competition very high in the global life sciences BPO market.

Obtain Report Details @ http://www.transparencymarketresearch.com/life-sciences-bpo-market.html

Demand for Outsourcing Solutions Surges as Pharma Companies Increasingly Focus on their Core Competencies

Demand for life sciences BPO solutions is expected to surge considerably in the forthcoming years. “With pharmaceutical companies revising their business strategies, they are more likely to outsource their non-core business activities to third-party solution providers,” said a lead TMR analyst. In the last five years, multinational companies such as Pfizer, GSK, and Novartis have already either divested or outsourced their noncore business activities to CMOs in order to enhance their core competencies. This trend is expected to take a bigger shape in the near future, thus fuelling demand for life sciences BPO services.

The global pharmaceutical industry is presently marred by the growing healthcare budget cuts and a decline in productive outcome of research and development. This has resulted in the drying of pipeline drugs. Furthermore, several blockbuster drugs are approaching their patent expiry, which has intensified the competition among drug developers. Hence, large pharmaceutical companies have started considering outsourcing their commercial manufacturing operations as a cost-effective strategy of effectively utilizing their limited resources.

Besides these, the increase in orphan drug development also encourages pharmaceutical companies to consider the services of a CMO. As an increasing number of pharmaceutical companies are shifting to orphan drug development, the prospects of life sciences outsourcing are surging.

Threat Regarding Breach of Proprietary Information Limits Proliferation of Life Sciences BPO Services

As per a TMR analyst, “Despite witnessing positive growth opportunities, issues pertaining to product quality and breach of pipeline-related information are limiting the proliferation of life sciences BPO services.” As pharmaceutical organizations increasingly become connected via cloud or social media channels, they are witnessing a spurt of potential threats. It is thus imperative for the life sciences industry to safeguard their proprietary information and highly sensitive personal data against breaches. Such issues pertaining to information breach often discourage pharma organizations to partner with CROs and CMOs.

Evolution of Novel Delivery Systems to Boost Demand for Life Sciences BPO Services

Nevertheless, the demand for life sciences BPO services is expected to surge in response to the increasing demand for biologic and biosimilar drugs. In the last couple of years, the industry supply chain has significantly evolved as a result of the growth witnessed in biologics. The rise in demand for manufacturing, packaging, and logistics components is thus noted across the pharmaceutical industry. This has made outsourcing services offered by life sciences BPO indispensable for pharma companies. Furthermore, due to the evolution of novel delivery forms such as transdermal patches, infusion therapies, and autoinjector devices, drug manufacturers are increasingly seeking outsourcing partners to control cost contingencies.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1782

In terms of services, the global life sciences BPO market can be segmented into pharmaceutical outsourcing and others. Contract research outsourcing (CRO) and contract manufacturing outsourcing (CMO) are the key segments of pharmaceutical outsourcing. Of these the CMO segment held the lion’s share in the market in 2014. Regionally, the global life sciences BPO market was led by North America.

As per Transparency Market Research, the global life sciences BPO market, which stood at US$127.4 bn in 2014, is expected to reach US$286.3 bn by the end of 2023. The market will thus exhibit a CAGR of 8.9% between 2015 and 2023.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.